lung nodules seen at a prior hospitalization earlier that year.While the nodules were unchanged, patchy airspace diseaseinvolving the let lower lobe was noted. The patient’s past medical history included Non Insulin De-pendent
, hyperlipidemia, hypertension, bron-chiectasis, asthma, rheumatic ever at age 22 and Bell’s palsy.Her medical issues, other than the productive cough, were sta-ble on medications.As a result o the patient’s persistent cough, several sputum sam-ples were obtained or culture. One o her many samples grew
Mycobacterium avium intracellulare
(MAI). Since the patient’sclinical presentation and imaging reports were suggestive o alung inection, she was treated or MAI. Subsequently, the pa-tient was prescribed Biaxin, ethambutol and riampin. Unortu-nately, the patient did not tolerate these medications well andher symptoms were not improving ater our weeks o therapy.Given these fndings, she was reerred to an Inectious Diseasespecialist or urther evaluation and management. The initial assessment indicated the patient was likely coloni-zed with MAI. A high resolution CT scan was obtained. This stu-dy showed evidence o bronchiectasis involving the basal seg-ments o both lobes as well as an area in the lingular region o the let upper lobe. The patient was reerred to a Pulmonologistor a bronchoscopy.Bronchial alveolar lavage samples rom both lungs were cultu-red by plating on blood agar, EMB and chocolate agar. Grampositive rods in the orm o diptheroids were noted, and 24,000colony orming units (cu) o
species appearedon media plates. Subsequently, these colonies were identifedas
by Vitek 2 ANC card (BioMérieux, Inc.,Durham NC). Fungal cultures were negative ater two weeks o incubation, and no acid ast bacilli were detected in multiplelung lavage and sputum specimens (14 in total). Incidentally,
showed up as a minor popula-tion (cu less than 1/10th o
was subjected to disk-diusion testingaccording to published CLSI (Clinical and Laboratory StandardsInstitute, ormerly NCCLS) guidelines to determine its antibioticsusceptibility profle. The bacterium was susceptible to amoxi-cillin/clavulanate, cephalothin, ciprooxacin, gentamicin, levo-oxacin, penicillin, trimethoprim/sulamethoxazole and van-comycin; on the other hand, it was resistant to clindamycin anderythromycin.Empirically, the patient was placed on a 10 day course o Leva-quin pending susceptibility results or the
was not treated due to itslow number and very small colony ormation seen rom cultu-ring o the bronchial lavage samples. The patient was ollowed
© Under License o Creative Commons Attribution 3.0 License This article is available rom:http://www.transbiomedicine.com
up a ew days later with signifcant clinical improvement. Atthat time, the patient’s susceptibility data was available. Sincethe bacterial isolate was susceptible to Levaquin, this antibioticwas continued or another 4 days or a total o 14-day therapy.Following the treatment course, the patient did quite well withresolution o her purulent sputum producing cough.
As a non-ermenting species o
is part o the normal oropharyngeal ora and it hasbeen documented to cause respiratory tract inections and en-docarditis [1-3]. Unlike
, this organism is oten ne-glected during routine clinical microbiology laboratory analy-sis. Nevertheless, it has been reported in cases o prostheticinections, sot tissue wounds, keratitis, conjunctivitis, and jointinections [1, 7]. In addition to recovering rom respiratory tractspecimens,
isolates have been associa-ted with inections in the urinary system as well as intravenoussites rom patients o dierent age groups and immunologicstatus .
is among the many pathogens respon-sible or causing pneumonia . Concerns have been raised orits role in immunocompromised patients, especially those withHIV inections [4, 6]. There is evidence indicating this bacteriumcan potentially inect immunocompetent individuals as well .Although not as prevalent as some other respiratory pathogensin causing community-acquired pneumonia (CAP), the numbero CAP incidences with
was signifcantenough to raise concerns in the medical community . This report describes a case o CAP that was acquired prior to aroutine doctor visit. The clinical eatures associated with bron-chiectasis were frst thought to be caused by MAI. When thepatient did not respond to medications and her symptomswere not subsiding, a decision was made to obtain bronchialalveolar lavage.
was cultured and iden-tifed rom this non-routine respiratory specimen. Its antibioticsusceptibility profle, specifcally the resistance to erythromycinand clindamycin, agreed with other reports . Administeringappropriate antimicrobial intervention to the patient allowedsuccessul arresting o her inection.While
is a rare organism causing CAP,this bacterium can produce a myriad o inections in an immu-nocompromised host. The patient presented in this report didhave a history o bronchiectasis, rheumatoid arthritis and Dia-betes Mellitus. Nevertheless, this case report does not minimizethe importance o recognizing MAI as a commensal organismin someone with pre-existing bronchiectasis. It can potentiallycause severe lung inections in the right clinical setting resul-